T Charles Witzel1, Alison J Rodger. 1. aSigma Research, Department of Social and Environmental Health Research, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine bResearch Department of Infection & Population Health, University College London, London, UK.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the most recent literature on outcomes and issues associated with HIV self-testing (HIVST). RECENT FINDINGS: HIVST is acceptable to a range of populations in a variety of contexts, particularly if users' values and preferences are taken into account in intervention development. Approaches being explored in ongoing and planned studies are the efficacy of HIVST to increase diagnosis of long-standing prevalent infections and to reduce the interval between HIV transmission and diagnosis, particularly in high-incidence groups. Though there is little evidence of harms related to HIVST, this remains a potential issue. Concerns remain about the reliability of currently available HIVST kits, which have lower sensitivity than testing options available in clinical settings, particularly in early HIV infection. Evidence on linkage to care for confirmatory testing after a reactive HIVST result and the cost-effectiveness of HIVST to increase rates of HIV diagnosis is currently limited. SUMMARY: HIVST is a relatively new innovation that is acceptable to key populations and which could increase HIV testing rates and rates of HIV diagnosis, especially in at-risk groups. Concerns remain about test sensitivity (particularly in early infection), and linkages to care for confirmatory testing after a reactive HIVST.
PURPOSE OF REVIEW: The purpose of this review is to describe the most recent literature on outcomes and issues associated with HIV self-testing (HIVST). RECENT FINDINGS: HIVST is acceptable to a range of populations in a variety of contexts, particularly if users' values and preferences are taken into account in intervention development. Approaches being explored in ongoing and planned studies are the efficacy of HIVST to increase diagnosis of long-standing prevalent infections and to reduce the interval between HIV transmission and diagnosis, particularly in high-incidence groups. Though there is little evidence of harms related to HIVST, this remains a potential issue. Concerns remain about the reliability of currently available HIVST kits, which have lower sensitivity than testing options available in clinical settings, particularly in early HIV infection. Evidence on linkage to care for confirmatory testing after a reactive HIVST result and the cost-effectiveness of HIVST to increase rates of HIV diagnosis is currently limited. SUMMARY: HIVST is a relatively new innovation that is acceptable to key populations and which could increase HIV testing rates and rates of HIV diagnosis, especially in at-risk groups. Concerns remain about test sensitivity (particularly in early infection), and linkages to care for confirmatory testing after a reactive HIVST.
Authors: Juan Hoyos; Tomás Maté; Juan-Miguel Guerras; Marta Donat; Cristina Agustí; Matthias Kuske; Ricardo Fuertes; Sophocles Chanos; Francois Pichon; Luis Sordo; José Pulido; María-José Belza Journal: Int J Environ Res Public Health Date: 2021-04-30 Impact factor: 3.390
Authors: T Charles Witzel; Peter Weatherburn; Alison J Rodger; Adam H Bourne; Fiona M Burns Journal: BMC Public Health Date: 2017-05-22 Impact factor: 3.295
Authors: Andy Guise; T Charles Witzel; Sema Mandal; Caroline Sabin; Tim Rhodes; Anthony Nardone; Magdalena Harris Journal: BMC Infect Dis Date: 2018-06-19 Impact factor: 3.090
Authors: T Charles Witzel; Michelle M Gabriel; Leanne McCabe; Peter Weatherburn; Mitzy Gafos; Andrew Speakman; Roger Pebody; Fiona M Burns; Chris Bonell; Fiona C Lampe; David T Dunn; Denise Ward; Justin Harbottle; Andrew N Phillips; Sheena McCormack; Alison J Rodger Journal: BMC Infect Dis Date: 2019-08-08 Impact factor: 3.090
Authors: T Charles Witzel; Peter Weatherburn; Adam Bourne; Alison J Rodger; Chris Bonell; Mitzy Gafos; Roy Trevelion; Andrew Speakman; Fiona Lampe; Denise Ward; David T Dunn; Michelle M Gabriel; Leanne McCabe; Justin Harbottle; Yolanda Collaco Moraes; Susan Michie; Andrew N Phillips; Sheena McCormack; Fiona M Burns Journal: Int J Environ Res Public Health Date: 2020-01-10 Impact factor: 3.390
Authors: T Charles Witzel; Ingrid Eshun-Wilson; Muhammad S Jamil; Nerissa Tilouche; Carmen Figueroa; Cheryl C Johnson; David Reid; Rachel Baggaley; Nandi Siegfried; Fiona M Burns; Alison J Rodger; Peter Weatherburn Journal: BMC Med Date: 2020-12-03 Impact factor: 8.775
Authors: Michelle M Gabriel; David T Dunn; Andrew Speakman; Leanne McCabe; Denise Ward; T Charles Witzel; Justin Harbottle; Simon Collins; Mitzy Gafos; Fiona M Burns; Fiona C Lampe; Peter Weatherburn; Andrew Phillips; Sheena McCormack; Alison J Rodger Journal: BMC Infect Dis Date: 2018-10-23 Impact factor: 3.090
Authors: T C Witzel; A Bourne; F M Burns; A J Rodger; L McCabe; M M Gabriel; M Gafos; D Ward; Y Collaco-Moraes; D T Dunn; A Speakman; C Bonell; R Pebody; F C Lampe; J Harbottle; A N Phillips; S McCormack; P Weatherburn Journal: HIV Med Date: 2019-12-10 Impact factor: 3.180